Dr Reddy's Labs announce launch of generic version of NitroDur

On Tuesday, Dr Reddy’s Laboratories Ltd along with its subsidiaries announced the launch of an authorised generic version of NitroDur (nitroglycerin) Transdermal Infusion System in the US market. NitroDur is a trademark of USpharma Ltd.

Dr Reddy’s Nitroglycerin Transdermal Infusion System is available in four dosage strengths, which are, 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, and 0.6 mg/hr, each in a box of 30 counts.

According to IMS Health and Quintiles (IQVIA Health), the combined sales for all Nitroglycerin Transdermal Patch products in the US market was approximately US$ 14.7 million MAT for the most-recent twelve months ending in January 2020.

Dr Reddy's Laboratories Limited is a pharmaceutical company operating in three segments, namely, global generics, pharmaceutical services and active ingredients as well as proprietary products.

On Monday, the stock closed at Rs 3,744.50, up by 3.49 per cent or Rs 126.35 per share. The 52-week high is recorded at Rs 3,853.85 and the 52-week low is Rs 2,352 on BSE.